Rivero-Ríos Pilar, Madero-Pérez Jesús, Fernández Belén, Hilfiker Sabine
Institute of Parasitology and Biomedicine "López-Neyra", Consejo Superior de Investigaciones Científicas (CSIC), Avda del Conocimiento s/n, 18016 Granada, Spain.
Curr Neuropharmacol. 2016;14(3):238-49. doi: 10.2174/1570159x13666151030103027.
Autophagy is a cellular quality control mechanism crucial for neuronal homeostasis. Defects in autophagy are critically associated with mechanisms underlying Parkinson's disease (PD), a common and debilitating neurodegenerative disorder. Autophagic dysfunction in PD can occur at several stages of the autophagy/lysosomal degradative machinery, contributing to the formation of intracellular protein aggregates and eventual neuronal cell death. Therefore, autophagy inducers may comprise a promising new therapeutic approach to combat neurodegeneration in PD. Several currently available FDA-approved drugs have been shown to enhance autophagy, which may allow for their repurposing for use in novel clinical conditions including PD. This review summarizes our current knowledge of deficits in the autophagy/lysosomal degradation pathways associated with PD, and highlight current approaches which target this pathway as possible means towards novel therapeutic strategies.
自噬是一种对神经元稳态至关重要的细胞质量控制机制。自噬缺陷与帕金森病（PD）的潜在机制密切相关，帕金森病是一种常见且使人衰弱的神经退行性疾病。PD中的自噬功能障碍可发生在自噬/溶酶体降解机制的几个阶段，导致细胞内蛋白质聚集体的形成并最终导致神经元细胞死亡。因此，自噬诱导剂可能构成一种有前景的新治疗方法，用于对抗PD中的神经退行性变。目前几种已获美国食品药品监督管理局（FDA）批准的药物已被证明可增强自噬，这可能使其能够重新用于包括PD在内的新临床病症。本综述总结了我们目前对与PD相关的自噬/溶酶体降解途径缺陷的认识，并强调了目前针对该途径的方法，作为实现新治疗策略的可能手段。
